About G1 Therapeutics
G1 Therapeutics is a Healthcare company based in Chapel Hill (United States) founded in 2008, and was acquired by Pharmacosmos in August 2024. Cancer therapeutics are developed via a proprietary kinase platform. It operates on a HealthTech model. G1 Therapeutics has raised $97.61 million across 12 funding rounds from investors including NIH, Franklin Templeton and TD Securities. The company has 100 employees. G1 Therapeutics offers products and services including Next Generation Cancer Therapies. Its focus areas include Biotechnology and Cancer Therapeutics. Its legal entity is G1 Therapeutics, Inc. Its competitors include Moderna, BeiGene and Incyte; 2 of its 3 listed competitors have raised funding.
Company details
G1 Therapeutics, Inc. is engaged in the development of next-generation therapies aimed at improving outcomes for cancer patients. The company operates within the healthcare sector, specifically targeting innovative solutions for cancer treatment. As a subsidiary of Pharmacosmos Therapeutics, it continues to advance survival rates through optimized chemotherapy approaches.
- Headquarters Chapel Hill, United States
- Employees 100
- Stage Acquired
- SectorsHealthcare
- Website category Health · Biotechnology and Pharmaceuticals
- Phone•••• ••••
- Website g1therapeutics.com
- Social LinkedIn X
- Acquired by Pharmacosmos (Aug 2024)
- Legal Name G1 Therapeutics, Inc.
- Annual Revenue$82.51 M (USD)61as on Dec 31, 2023
- Net Profit-$47.97 M (USD)67as on Dec 31, 2023
- EBITDA-$39.53 M (USD)71as on Dec 31, 2023
- Total Equity Funding$97.61M (USD)
in 12 rounds
- Latest Funding Round$38.4M (USD), Post-IPO
Jun 2018
- InvestorsNIH
& 15 more
- Employee Count100
- Acquired byPharmacosmos
(Aug 2024)
Products & Services of G1 Therapeutics
G1 Therapeutics offers a comprehensive portfolio of products and services, including Next Generation Cancer Therapies.
Therapies are developed to improve cancer patient outcomes.
Funding Insights of G1 Therapeutics
G1 Therapeutics has successfully raised a total of $97.61M across 12 strategic funding rounds. The most recent funding activity was a Post-IPO round of $38.4 million completed in June 2018. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $97.61M
- Total Rounds 12
- Last Round Post-IPO — $38.4M
- First Round $692,326
(Aug 2009)
- Investors Count 15
Latest 10 of 12 funding rounds of G1 Therapeutics with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jun 2018 | $38.4M | Post-IPO | – | – | – |
| Jul 2016 | $50M | Series C | – | – | |
| Feb 2015 | $33M | Series B | – | Eshelman Ventures, RA Capital Management | |
| Jun 2014 | $12.6M | Series A | – | MedImmune Ventures | |
| Aug 2013 | $1.25M | Seed | – | – | – |
| Apr 2013 | $159,836 | Grant | – | – | |
| Nov 2012 | $250,000 | Debt – Venture | – | – | |
| Oct 2012 | $762,884 | Seed | – | Hatteras Venture Partners | – |
| Jun 2012 | $1M | Grant | – | – | |
| Sep 2011 | $3M | Grant | – | – |
16 investors in total: 16 institutional.
Investors in G1 Therapeutics
G1 Therapeutics has secured backing from 16 investors, including institutional and venture fund investors. Prominent investors backing the company include NIH, Franklin Templeton and TD Securities.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Early-stage and late-stage biotech and finance companies are funded. | rockspringscapital.com | Baltimore, United States | ||
| eshelmanventures.com | ||||
Tech & Life Sciences focused VC firm investing in early stage companies in the US & Europe | hatterasvp.com | Durham, United States | ||
Lumira Ventures is engaged in life sciences venture capital investment. | lumiraventures.com | Toronto, Canada | ||
| medimmuneventures.com | ||||
Venture capital is directed toward life sciences and technology sectors. | mtngp.com | Nashville, United States | ||
Biotech startups are funded by this venture capital firm. | boxercap.com | San Diego, United States | ||
Venture capital firm focused on healthcare startups | solasta-ventures.com | Boston, United States | ||
Biotech startups are incubated and funded in North Carolina. | 1984 | ncbiotech.org | Durham, United States | |
Corporate finance advisory, mergers, acquisitions, and investment services are provided. | 1918 | cowen.com | New York, United States |
Investor details for G1 Therapeutics
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of G1 Therapeutics
12 people are tracked at G1 Therapeutics (3 in leadership, 3 in board & advisors, 6 in team); the tracked headcount is 100.
| Name | Role | Group |
|---|---|---|
Raj Malik | Chief Medical Officer | Leadership |
Darlene Burns | Director, Key Customer Marketing | Leadership |
Monica Thomas | General Counsel & Chief Compliance Office | Leadership |
Glenn P. Muir | Director | Board & advisors |
Jacks Lee | Director | Board & advisors |
Norman E. Sharpless | Director | Board & advisors |
Shannon Lim | Medical Science Liaison | Team |
Zaida Padron | Oncology Account Manager | Team |
Maggie Gagnon | Manager, clinical operations | Team |
Olu O. Oyeneye | Sr Infrastructure /DevOps Eng. | Team |
Mike Townsend | Principal Solutions Architect | Team |
Bobirjon Mukamilov | Financial Planning and Analysis Manager | Team |
Complete people profiles for G1 Therapeutics
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of G1 Therapeutics
5 dated milestones of G1 Therapeutics across 16 years, from founding to its latest funding, stage changes and deals.
- Founded G1 Therapeutics is founded.
- Funding First funding round of $692K.
- IPO Lists on the stock exchange (IPO).
- Funding Latest funding round, Post-IPO, of $38.4M.
- Exit Acquired by Pharmacosmos.
Competitors of G1 Therapeutics
G1 Therapeutics has 3 listed competitors in our database, 2 of them funded. They include Moderna, BeiGene and Incyte.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| modernatx.com | 2010 | Cambridge, United States | $2.78B | 1,312 | mRNA-based therapeutics for diseases including cancer and infections are developed. | |
| beigene.com | 2010 | Cambridge, United States | $172M | 1,090 | Targeted and immune-oncology drugs for cancer treatment are developed. | |
| incyte.com | 1991 | Wilmington, United States | 1,387 | Small molecules are developed for cancer and skin disease treatments. |
Detailed competitors of G1 Therapeutics
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of G1 Therapeutics
The website of G1 Therapeutics (g1therapeutics.com) receives about 2.8K visits a month and ranks #6,603,375 among all websites worldwide, #6,660 in Biotechnology and Pharmaceuticals.
- Monthly visits2.8K
▲ 15.5% vs previous month
- Unique visitors1K
per month
- Global rank#6,603,375
among all websites
- Category rank#6,660
Health · Biotechnology and Pharmaceuticals
- Bounce rate43%
- Pages per visit1.8
- Average visit33 sec
- DevicesDesktop 29% · Mobile 71%
Websites whose visitors overlap most with G1 Therapeutics. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| genorbio.com | 100% | View details | |||
| abeonatherapeutics.com | 76% | 8K | #2,941,685 | View details | |
| orexigen.com | 73% | View details | |||
| aerpio.com | 73% | View details | |||
precisiontherapeutics.com | precisiontherapeutics.com | 72% | – | ||
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
All 18 similar websites and full traffic analytics for G1 Therapeutics
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 18 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Top companies in Oncology
3 companies that operate in the same segment as G1 Therapeutics (Oncology) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Digital sequencing technology for cancer detection is developed. | 2012 | Redwood City, California, United States | USD 557.5 M | USD 982.02 M | 4,867 | |
Circulating tumor DNA is screened for early cancer detection. | 2016 | Menlo Park, California, United States | USD 2 B | USD 147.17 M | 1,141 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about G1 Therapeutics
Complete news archive for G1 Therapeutics
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about G1 Therapeutics
G1 Therapeutics was founded in 2008 and raised its 1st funding round 1 year after it was founded.
G1 Therapeutics is headquartered in Chapel Hill, United States. It is registered at Chapel Hill, North Carolina, United States.
G1 Therapeutics is a funded company, having raised a total of $97.61M across 12 funding rounds to date. The company's 1st funding round was a Grant of $3M, raised on Aug 2009.
G1 Therapeutics has 100 employees.
Annual revenue of G1 Therapeutics is $82.51M as on Dec 31, 2023.
G1 Therapeutics, Inc. is engaged in the development of next-generation therapies aimed at improving outcomes for cancer patients. The company operates within the healthcare sector, specifically targeting innovative solutions for cancer treatment. As a subsidiary of Pharmacosmos Therapeutics, it continues to advance survival rates through optimized chemotherapy approaches.
G1 Therapeutics offers Next Generation Cancer Therapies.
G1 Therapeutics has 16 investors. Key investors include NIH, Franklin Templeton, TD Securities, HHS, and RA Capital.
G1 Therapeutics operates through G1 Therapeutics, Inc..
Yes. G1 Therapeutics was acquired by Pharmacosmos in August 2024.